Immutep

Update in progress

IMMP (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Immutep Limited is an Australian biotechnology company developing LAG-3–based immunotherapies for cancer and autoimmune diseases. Its lead candidate, eftilagimod alfa (efti/IMP321), is a soluble LAG-3 fusion protein. The company also develops multiple programs, including TACTI and INSIGHT series, in various clinical stages, and collaborates with Merck, EOC Pharma, Novartis, and Labcorp. Formerly Prima BioMed, it was renamed in 2017 and is based in Sydney, founded in 1987.

Company score

Sentiment: -0.40; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: -0.01; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: -0.16; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.05; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: -0.06; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.23; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive